Equities

ConvaTec Group PLC

CTEC:LSE

ConvaTec Group PLC

Health CareMedical Equipment and Services
  • Price (GBX)225.60
  • Today's Change-1.60 / -0.70%
  • Shares traded6.12m
  • 1 Year change-4.65%
  • Beta0.7753
Data delayed at least 20 minutes, as of Feb 06 2026 16:43 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year ConvaTec Group PLC grew revenues 6.85% from 2.14bn to 2.29bn while net income improved 46.20% from 130.30m to 190.50m.
Gross margin55.90%
Net profit margin9.20%
Operating margin15.07%
Return on assets5.86%
Return on equity12.50%
Return on investment6.63%
More ▼

Cash flow in USDView more

In 2024, cash reserves at ConvaTec Group PLC fell by 32.90m. However, the company earned 396.20m from its operations for a Cash Flow Margin of 17.31%. In addition the company used 160.80m on investing activities and also paid 263.80m in financing cash flows.
Cash flow per share0.1568
Price/Cash flow per share13.60
Book value per share0.6493
Tangible book value per share-0.1104
More ▼

Balance sheet in USDView more

ConvaTec Group PLC has a Debt to Total Capital ratio of 42.52%, a lower figure than the previous year's 84.05%.
Current ratio1.95
Quick ratio1.15
Total debt/total equity0.7398
Total debt/total capital0.4252
More ▼

Growth rates in USD

Year on year, growth in dividends per share fell -5.90% while earnings per share excluding extraordinary items rose 45.90%. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is the highest in its industry.
Div yield(5 year avg)2.20%
Div growth rate (5 year)1.20%
Payout ratio (TTM)64.28%
EPS growth(5 years)79.57
EPS (TTM) vs
TTM 1 year ago		41.49
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.